IDEX Q3 sales rise 10% to $879 million; diluted EPS $1.70, full-year EPS range narrowed
IDEX reported third-quarter 2025 results, with net sales up 10% on a reported basis to $878.7 million and GAAP diluted EPS up 8% to $1.70. The company narrowed its full-year 2025 GAAP diluted EPS outlook to $6.35 to $6.40 and raised its share repurchase authorization to $1 billion, which matters to shareholders because it signals continued capital returns alongside growth.
Key points
- Q3 2025 net sales of $878.7 million rose 10% reported and 5% organically, helped by the Mott acquisition.
- GAAP diluted EPS was $1.70 and adjusted diluted EPS was $2.03, up 8% and 7% respectively.
- Full-year 2025 adjusted diluted EPS narrowed to $7.86 to $7.91, within prior guidance; organic sales growth of about 1% was unchanged.
- The company repurchased $75 million of shares in Q3 2025 and $175 million year-to-date, and increased its authorization to $1 billion.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.